Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Addaction

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

- PMLiVE

Humira gains EU licence first for Hidradenitis Suppurativa

Thirteenth licence for the drug in Europe

- PMLiVE

Access to new hep C treatments put under the spotlight

NICE plans to restrict use of BMS’ Daklinza follow funding delay for Gilead's Sovaldi

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

Paradigm Comms and Trio Health win healthcare media relations award

Judges said the campaign was a true ‘vehicle for action and change’

- PMLiVE

Lucid wins med ed consultancy award at Communiqué

It also sees success with a professional education programme for AbbVie

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

China flag thumb

China turns down one of two Sovaldi patents

Advocacy group attempting to block drug in other emerging markets too

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

- PMLiVE

NHS England sets up new £190m hep C fund

Will see patients gain access to treatments from Gilead and AbbVie

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links